Welcome to the Marbach Castle Drug-Drug Interaction Workshop Series
The DDI workshop series is a non-profit programme to exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
The overall objective of the international Marbach Castle DDI Workshop series is to improve and disseminate the scientific knowledge about drug-drug interactions (incl. food-drug and herb-drug interactions), and to foster communication for efficient preclinical and clinical investigation of DDIs across disciplines and organisational boarders.
The goal is safer use of pharmaceutical products especially in geriatric and medically complex patient populations with various co-morbidities and increasing poly-pharmacotherapy.
For the DDI Workshop 2027, again we have a number of outstanding speakers covering important topics, see our Programme.
SAVE THE DATE – DDI Workshop 2027
The upcoming Workshop will take place from June 6th to June 8th, 2027.
The Workshop Programme 2027
17th DDI Workshop, June 6th – June 8th, 2027
In its 17th year, the Marbach Workshop brings together international experts to discuss current topics in drug-drug interactions (DDIs). Held June 6–8, 2027, the workshop will update attendees on recent scientific advances, regulatory expectations, and clinical applications.
Following registration, the famous cycling tour and a very focused poster presentation on Sunday, June 6, the workshop starts Monday, June 7, 2027, with Session I: Latest Update in Key DDI Areas. Presentations will cover AI and DDI evaluation, high-throughput robotic assessment of DDI liability in early discovery, DDIs beyond small molecules, and end with a sophisticated discussing on translation models for transporter DDI data.
Session II follows up on transporter related DDIs but focuses on its regulatory aspects, including IQ PBPK Transporter Working Group outcomes and implications of the ICH guidelines, generating in vitro data to characterize transporter DDIs, perspectives from a regulatory scientist, a critical analysis of regulatory submissions, and a panel debate.
On Tuesday, June 8, Session III covers optimizing DDI-related information in clinical trials and clinical practice, including the clarity and completeness of DDI information in trial protocols and drug labels, managing comedications in oncology, efforts to harmonize label language, and again panel debate.
Session IV addresses drugs with specific challenges for studying DDIs, including time-dependent DDI dynamics and DDIs involving metabolically stable drugs with slow elimination.
Session V focuses on DDIs of drugs with new modalities (such as PROTACs and ADCs), including PBPK modeling to predict DDIs with therapeutic proteins, followed by a joint panel discussion. At the point in time of the first announcement, the precise titles of the presentations remain to be determined.
As always in this workshop series, interactive discussions will play an outstanding role. Participants are encouraged to submit abstracts for poster presentations, which will be featured in the Sunday-evening poster heat and more extensively during coffee breaks. Overall, the workshop aims at providing many opportunities for exchanging information and for networking.
The Faculty
Uwe Fuhr, MD
Dr. Wafaâ Jabrane
Isabelle Ragueneau-Majlessi, MD
Amin Rostami-Hodjegan, PhD, FCP
Ping Zhao, PhD
Supporting organisations
